|
Understanding the Role of Polyautoimmunity in Rheumatic Diseases
|
An estimated 5 percent of the world’s population is diagnosed with one of a group of heterogeneous autoimmune rheumatic diseases (ARDs) including systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), and Sjogren’s syndrome (SS). Not only do these diseases share mechanisms and risk factors, they are often comorbid conditions recognized as polyautoimmune (PolyA) manifestations of the same underlying dysfunction.
|
|
Read more
|
|
|
|
EULAR/ACR Treatment Guidelines for Polymyalgia Rheumatica
|
| Polymyalgia rheumatica treatment varies significantly in glucocorticoid dosages, tapering strategies and DMARD use. EULAR and ACR have published treatment recommendations. In this slideshow, we highlight the recommendations. |
|
Read more
|
|
|
|
Q&A: Dr. Jim Oates on Hard-to-Treat Lupus in Black Patients
|
| The prevalence of systemic lupus erythematosus (SLE) is higher among black patients. They can present with a worsened disease state and mortality rates can be higher. This suggests a need for better therapeutic options, says Jim C. Oates, M.D., of Medical University of South Carolina. In this Q&A, Dr. Oates addresses treatment challenges black patients face. |
|
Read more
|
|
|
